Biopsy and re-biopsy for PD-L1 expression in NSCLC. association between PD-L1 and checkpoint inhibitor efficacy through treatment in NSCLC. A pilot study. (2nd November 2021)

• Record Type: Journal Article
• Authors: Zarogoulidis, Paul; Petridis, Dimitris; Huang, Haidong; Bai, Chong; Hohenforst-Schmidt, Wolfgang; Freitag, Lutz; Baka, Sofia; Drougas, Dimitris; Vagionas, Anastasios; Tsakiridis, Kosmas; Turner, J Francis; Hatzibougias, Dimitris; Boukovinas, Ioannis; Zaric, Bojan; Kovacevic, Tomi; Ioannidis, Aris; Courcoutsakis, Nikolaos; Matthaios, Dimitris; Sardeli, Chrisanthi
• Is Part Of: Expert review of respiratory medicine. Volume 15:Number 11(2021)
• Page Start: 1483
• Page End: 1491
• Publication Date: 2021-11-02
• Subjects: NSCLC -- EBUS -- PD-L1 -- adenocarcinoma -- squamus -- DAKO -- survival -- biopsy -- re-biopsy; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1080/17476348.2021.1987888
• Languages: English
• ISSNs: 1747-6348

Abstract

ABSTRACT: Introduction: Lung cancer is diagnosed at a late stage due to lack of early disease symptoms. Therefore an efficient treatment is necessary for prolonged disease free survival. Patients and Methods: In our study we recruited 124 patients NSCLC patients with adenocarcinoma and squamus cell carcinoma. All recuited patients had Programmed death-ligand 1 expression ≥50 (PD-L1)with DAKO technique. Immunotherapy was administered with as first line treatment. Re-biopsies were performed in the main lung lesion every 4 months with the restaging of the patient and also in the metastastic sites in other organs that occurred during treatment. PD-L1 expressed was evaluated in the biopsies of the metastatic sites. Results: It appears thereafter that the PD-L1 expression could easily be claimed as a promising bio-index with a cutoff value 65, below which a negative prognosis of the disease progress will be evident and above that value a positive continuation of the disease will be prominent. Conclusion: The findings of this study suggest that the PD-L1-65 index works adequately either concerning the neo-metastatic sites or the patient disease responses. Re-biopsies in new metastastic sites are necessary since we probably have a new cancer and chemotherapy should be added. More studies should confirm are results and change the NSCLC treatment approach of these patients.